	ProstateCancer – D	rgDisAdr_BbsiProx_c	entre – nb – SMOTE		100
					[DrgDis] Malignant neoplasm of prostate (C0376358)[DisGeNET_curated]
					[DrgDis] Adenocarcinoma of prostate (C0007112)[DisGeNET_curated]
					[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_GA] 40
					[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_GA]
					[DrgDis] prostate cancer (MONDO_0008315)[OpenTargets_GA]
					[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_RNA]
					[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_RNA]
					[DrgDis] prostate adenocarcinoma (EFO_0000673)[OpenTargets_literature]
					[DrgDis] prostate carcinoma (EFO_0001663)[OpenTargets_literature]
					[DrgDis] metastatic prostate cancer (EFO_0000196)[OpenTargets_literature]
					[DrgDis] prostate cancer (MONDO_0008315)[OpenTargets_literature]
					[DrgDis] Prostate Small Cell Carcinoma (EFO_1000499)[OpenTargets_literature]
					[DrgDis] Cancer of prostate GSE1413[Enrichr_GeoDiseaseSig_Up]
					[DrgDis] Cancer of prostate GSE1413[Enrichr_GeoDiseaseSig_Down]
					[DrgDis] Prostate adenocarcinoma (PRAD)[Intogen]
					[DrgDis] Prostatic Neoplasms[PharmGKB_associated]
					[DrgDis] Prostate carcinoma (EFO_0001663)[ThETA]
					[DrgAdr] Adverse reaction (08.06.01.018) [ADReCS]
					[DrgAdr] Poisoning (12.03.01.004) [ADReCS]
					[DrgAdr] Neurotoxicity (12.03.01.011) [ADReCS]
					[DrgAdr] Neurotoxicity Syndromes (MESH:D020258) [CTD]
					[DrgAdr] Chemical and Drug Induced Liver Injury (MESH:D056486) [CTD]
					[DrgAdr] Cardiotoxicity (MESH:D066126) [CTD]
					[DrgAdr] Chemically–Induced Liver Toxicity (C4279912) [DisGeNET]
					[DrgAdr] Cardiotoxicity (C0876994) [DisGeNET]
					[DrgAdr] Drug toxicity (C0013221) [DisGeNET]
					[DrgAdr] Neurotoxicity Syndromes (C0235032) [DisGeNET]
Fold1	Fold2	Fold3	Fold4	Fold5	